Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

“KarXT是继20世纪50年代初第一代抗精神病药氯丙嗪诞生后，首款采用全新作用机制的抗精神病药物，两者相差70年左右。KarXT的获批有望为精神分裂症患者带来更多治疗选择。”9月27日，北京回龙观医院精神科主任医师陈松告诉人民日报健康客户端记者。

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...

Bristol Myers Squibb BMY announced that the FDA has approved xanomeline and trospium chloride (formerly KarXT), an oral ...

On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...